Most Recent Articles by Diana Ernst, RPh
The Food and Drug Administration (FDA) has approved Heplisav-B for the prevention of infection caused by all known subtypes of hepatitis B virus.
The Advisory Committee on Immunization Practices has released the guidelines for the 2017-2018 season.
The FDA Drug Interactions section has been updated to include revised information on concomitant use of corticosteroids with these drugs.
Among GERD patients, the mean annual ARI episode dropped from 4.39 during the year before PPI treatment to 3.89 after treatment with a PPI.
The GOLD Report includes a revised definition of COPD and updates guidelines for managing exacerbations.